Hormonal
GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.
For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.
Our data illustrate the superior efficacy of GLP1/E vs. other multi-agonists and metformin in the management of metabolic complications of PCOS
Why this rating
High-quality preclinical evidence in two distinct mouse models with consistent results, though not human trials.
Source
Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy
Miguel A. Sánchez-Garrido et al. · Nature Communications · 2024
DOI 10.1038/s41467-024-52898-y
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →